FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386032818> ?p ?o ?g. }

• W4386032818 abstract "<div>Purpose:<p>Glioblastoma multiforme (GBM) is a hypoxic tumor resistant to radiotherapy. The purpose of this study was to assess the safety and efficacy of a novel oxygen therapeutic, dodecafluoropentane emulsion (DDFPe), in chemoradiation treatment of GBM.</p>Experimental Design:<p>In this multicenter phase Ib/II dose-escalation study, patients were administered DDFPe via intravenous infusion (0.05, 0.10, or 0.17 mL/kg) while breathing supplemental oxygen prior to each 2 Gy fraction of radiotherapy (30 fractions over 6 weeks). Patients also received standard-of-care chemotherapy [temozolomide (TMZ)]. Serial MRI scans were taken to monitor disease response. Adverse events were recorded and graded. TOLD (tissue oxygenation level–dependent) contrast MRI was obtained to validate modulation of tumor hypoxia.</p>Results:<p>Eleven patients were enrolled. DDFPe combined with radiotherapy and TMZ was well tolerated in most patients. Two patients developed delayed grade 3 radiation necrosis during dose escalation, one each at 0.1 and 0.17 mL/kg of DDFPe. Subsequent patients were treated at the 0.1 mL/kg dose level. Kaplan–Meier analysis showed a median overall survival of 19.4 months and a median progression-free survival of 9.6 months, which compares favorably to historical controls. Among 6 patients evaluable for TOLD MRI, a statistically significant reduction in tumor T₁ was observed after DDFPe treatment.</p>Conclusions:<p>This trial, although small, showed that the use of DDFPe as a radiosensitizer in patients with GBM was generally safe and may provide a survival benefit. This is also the first time than TOLD MRI has shown reversal of tumor hypoxia in a clinical trial in patients. The recommended dose for phase II evaluation is 0.1 mL/kg DDFPe.</p><p>Trial Registration: NCT02189109</p>Significance:<p>This study shows that DDFPe can be safely administered to patients, and it is the first-in-human study to show reversal of hypoxia in GBM as measured by TOLD MRI. This strategy is being used in a larger phase II/III trial which will hopefully show a survival benefit by adding DDFPe during the course of fractionated radiation and concurrent chemotherapy.</p></div>" @default.
• W4386032818 created "2023-08-22" @default.
• W4386032818 creator A5005677013 @default.
• W4386032818 creator A5014504608 @default.
• W4386032818 creator A5015321314 @default.
• W4386032818 creator A5018355869 @default.
• W4386032818 creator A5039851337 @default.
• W4386032818 creator A5070747321 @default.
• W4386032818 creator A5071868334 @default.
• W4386032818 creator A5080500724 @default.
• W4386032818 creator A5085923503 @default.
• W4386032818 creator A5090381580 @default.
• W4386032818 date "2023-08-21" @default.
• W4386032818 modified "2023-09-25" @default.
• W4386032818 title "Data from Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme" @default.
• W4386032818 doi "https://doi.org/10.1158/2767-9764.c.6760500.v1" @default.
• W4386032818 hasPublicationYear "2023" @default.
• W4386032818 type Work @default.
• W4386032818 citedByCount "0" @default.
• W4386032818 crossrefType "posted-content" @default.
• W4386032818 hasAuthorship W4386032818A5005677013 @default.
• W4386032818 hasAuthorship W4386032818A5014504608 @default.
• W4386032818 hasAuthorship W4386032818A5015321314 @default.
• W4386032818 hasAuthorship W4386032818A5018355869 @default.
• W4386032818 hasAuthorship W4386032818A5039851337 @default.
• W4386032818 hasAuthorship W4386032818A5070747321 @default.
• W4386032818 hasAuthorship W4386032818A5071868334 @default.
• W4386032818 hasAuthorship W4386032818A5080500724 @default.
• W4386032818 hasAuthorship W4386032818A5085923503 @default.
• W4386032818 hasAuthorship W4386032818A5090381580 @default.
• W4386032818 hasConcept C126322002 @default.
• W4386032818 hasConcept C143998085 @default.
• W4386032818 hasConcept C197934379 @default.
• W4386032818 hasConcept C2776194525 @default.
• W4386032818 hasConcept C2776428644 @default.
• W4386032818 hasConcept C2776694085 @default.
• W4386032818 hasConcept C2777389519 @default.
• W4386032818 hasConcept C2779081379 @default.
• W4386032818 hasConcept C2989005 @default.
• W4386032818 hasConcept C502942594 @default.
• W4386032818 hasConcept C509974204 @default.
• W4386032818 hasConcept C71924100 @default.
• W4386032818 hasConcept C90924648 @default.
• W4386032818 hasConceptScore W4386032818C126322002 @default.
• W4386032818 hasConceptScore W4386032818C143998085 @default.
• W4386032818 hasConceptScore W4386032818C197934379 @default.
• W4386032818 hasConceptScore W4386032818C2776194525 @default.
• W4386032818 hasConceptScore W4386032818C2776428644 @default.
• W4386032818 hasConceptScore W4386032818C2776694085 @default.
• W4386032818 hasConceptScore W4386032818C2777389519 @default.
• W4386032818 hasConceptScore W4386032818C2779081379 @default.
• W4386032818 hasConceptScore W4386032818C2989005 @default.
• W4386032818 hasConceptScore W4386032818C502942594 @default.
• W4386032818 hasConceptScore W4386032818C509974204 @default.
• W4386032818 hasConceptScore W4386032818C71924100 @default.
• W4386032818 hasConceptScore W4386032818C90924648 @default.
• W4386032818 hasLocation W43860328181 @default.
• W4386032818 hasOpenAccess W4386032818 @default.
• W4386032818 hasPrimaryLocation W43860328181 @default.
• W4386032818 hasRelatedWork W2022976025 @default.
• W4386032818 hasRelatedWork W2036862336 @default.
• W4386032818 hasRelatedWork W2073885660 @default.
• W4386032818 hasRelatedWork W2156330848 @default.
• W4386032818 hasRelatedWork W2185575684 @default.
• W4386032818 hasRelatedWork W2390408846 @default.
• W4386032818 hasRelatedWork W2740663609 @default.
• W4386032818 hasRelatedWork W3032872084 @default.
• W4386032818 hasRelatedWork W3173223947 @default.
• W4386032818 hasRelatedWork W3194058763 @default.
• W4386032818 isParatext "false" @default.
• W4386032818 isRetracted "false" @default.
• W4386032818 workType "article" @default.